



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	199753	Die Da Fang a.k.a. Dragon's Blood & Notoginseng Sports Injury Formula
ARTG entry for	Medicine Listed	
Sponsor	Sun Herbal Pty Ltd	
Postal Address	Unit 5/25 Garema Cct, Kingsgrove, NSW, 2208 Australia	
ARTG Start Date	4/08/2012	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

This medicine contains a preparation of Carthamus tinctorius flower for oral use. From 1 July 2011 all Listed Medicines containing preparations of Carthamus tinctorius flower for oral use must include the label advisory statement 'Do not use if pregnant or likely to become pregnant'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Die Da Fang a.k.a. Dragon's Blood & Notoginseng Sports Injury Formula

Product Type	Single Medicine Product	Effective Date	23/04/2018
--------------	-------------------------	----------------	------------

Permitted Indications

- Traditionally used in Chinese medicine to invigorate/activate Blood
- Traditionally used in Chinese medicine to eliminate/reduce/remove/resolve/dissipate blood-stasis
- Traditionally used in Chinese medicine to unblock/open/relax channels
- Traditionally used in Chinese medicine to enrich/nourish/tonify/fortify/strengthen kidneys
- Traditionally used in Chinese medicine to calm/soothe/nourish the liver

Indication Requirements

- If TCM terminology is used on medicine label, label statement: Talk to a TCM practitioner/health professional if you are unsure if this medicine is right for you.
- Product presentation must not imply or refer to serious cardiovascular conditions.
- Product presentation must not imply or refer to liver disease, such as cirrhosis, hepatitis.
- Product presentation must not imply or refer to kidney disease.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings



Australian Government
Department of Health and Aged Care
 Therapeutic Goods Administration

Do not use if pregnant or likely to become pregnant (or words to that effect)

For practitioner dispensing only.

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

Angelica polymorpha root Extract dry concentrate	18.84 mg
Equivalent: Angelica polymorpha (Dry)	113.04 mg
Boswellia carterii gum oleoresin Extract dry concentrate	11.31 mg
Equivalent: Boswellia carterii (Dry)	67.86 mg
Caesalpinia sappan stem heartwood Extract dry concentrate	11.31 mg
Equivalent: Caesalpinia sappan (Dry)	67.86 mg
Carthamus tinctorius flower Extract dry concentrate	11.31 mg
Equivalent: Carthamus tinctorius (Dry)	67.86 mg
Citrus aurantium fruit Extract dry concentrate	11.31 mg
Equivalent: Citrus aurantium (Dry)	67.86 mg
Commiphora myrrha gum oleoresin Extract dry concentrate	11.31 mg
Equivalent: Commiphora myrrha (Dry)	67.86 mg
Corydalis turtschaninovii rhizome Extract dry concentrate	18.84 mg
Equivalent: Corydalis turtschaninovii (Dry)	113.04 mg
Curcuma longa rhizome Extract dry concentrate	11.31 mg
Equivalent: Curcuma longa (Dry)	67.86 mg
Curcuma zedoaria rhizome Extract dry concentrate	11.31 mg
Equivalent: Curcuma zedoaria (Dry)	67.86 mg
Cyathula officinalis root Extract dry concentrate	15.06 mg
Equivalent: Cyathula officinalis (Dry)	90.36 mg
Daemonorops draco sap resin Extract dry concentrate	11.31 mg
Equivalent: Daemonorops draco (Dry)	67.86 mg
Dipsacus asper root Extract dry concentrate	11.31 mg
Equivalent: Dipsacus asper (Dry)	67.86 mg
Drynaria fortunei rhizome Extract dry concentrate	11.31 mg
Equivalent: Drynaria fortunei (Dry)	67.86 mg
Glycyrrhiza uralensis root Extract dry concentrate	6.27 mg
Equivalent: Glycyrrhiza uralensis (Dry)	37.62 mg
Paeonia lactiflora root Extract dry concentrate	18.84 mg
Equivalent: Paeonia lactiflora (Dry)	113.04 mg
Paeonia suffruticosa stem bark Extract dry concentrate	11.31 mg
Equivalent: Paeonia suffruticosa (Dry)	67.86 mg
Paeonia veitchii root Extract dry concentrate	18.84 mg
Equivalent: Paeonia veitchii (Dry)	113.04 mg
Panax notoginseng root Extract dry concentrate	7.53 mg
Equivalent: Panax notoginseng (Dry)	45.18 mg
Platycodon grandiflorus root Extract dry concentrate	11.31 mg

Public Summary



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Equivalent: Platycodon grandiflorus (Dry)	67.86 mg
Prunus persica seed Extract dry concentrate	11.31 mg
Equivalent: Prunus persica (Dry)	67.86 mg
Salvia miltiorrhiza root Extract dry concentrate	18.84 mg
Equivalent: Salvia miltiorrhiza (Dry)	113.04 mg
Saposhnikovia divaricata root Extract dry concentrate	11.31 mg
Equivalent: Saposhnikovia divaricata (Dry)	67.86 mg
Siphonostegia chinensis herb Extract dry concentrate	11.31 mg
Equivalent: Siphonostegia chinensis (Dry)	67.86 mg
Sparganium stoloniferum tuber Extract dry concentrate	11.31 mg
Equivalent: Sparganium stoloniferum (Dry)	67.86 mg

Other Ingredients (Excipients)

Agar
carrageenan
hypromellose
sodium citrate dihydrate
soluble maize starch

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary